Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-1356

ABSTRACT: Transcription profiling by array of H. sapiens acute myeloid leukemia mononuclear cells to investigate associations with distinct clinical and genetic features and lack KIT mutations

PROVIDER: E-MTAB-1356 | ExpressionAtlas | 2025-01-23

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-1356-analysis-methods.tsv	Tabular
	E-MTAB-1356-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-1356-configuration.xml	Xml
	E-MTAB-1356-configuration.xml.beforeQC	Xml
	E-MTAB-1356-percentile-ranks.tsv	Tabular

Items per page:

1 - 5 of 47

Similar Datasets

E-GEOD-77846

Project description:Transcription profiling by high throughput sequencing of c-KIT+ splenocytes from murine acute myeloid leukemia and myeloproliferative neoplasm

2019-05-14 | E-GEOD-77846 | ExpressionAtlas

Phosphoproteomic profiling of D816V-KIT cells

Project description:Acute Myeloid Leukaemia (AML) carries a 5 year survival rate of just 24%. Toxic chemotherapy regimens remain the backbone of standard of care for AML. The KIT tyrosine kinase is a recognised AML oncogene, associated with poor outcome. We recently identified DNA-PK as a novel therapeutic target in FLT3 mutant AML. The similarity between KIT and FLT3 regulated signalling pathways led us to investigate DNA-PK in KIT-mutant AML.

2023-01-26 | PXD030005 | Pride

Search for a novel therapeutic target in myeloid leukemia

Project description:Antibody-based therapy for cancer is now one of the most successful and important strategies for treating patients with hematological malignancies. However, the lack of efficient tumor-associated antigens restricts the targeting therapy of myeloid leukemia. Analysis of the gene expression proï¬les of primary bone marrow samples from human acute myeloid leukemia (AML) patients or healthy donors was to identify and expand novel targets for the treatment of myeloid leukemias. we found that epithelial cell adhesion molecule (EpCAM) is overexpressed in patients with AML. we analyzed the gene expression proï¬les of bone marrow mononuclear cells from 2 human acute myeloid leukemia (AML) patients and 2 healthy donors using an oligonucleotide microarray, to identify up-regulated genes in AML samples comparing with healthy tissues.

2016-05-14 | E-GEOD-79605 | biostudies-arrayexpress

Synergistic targeting of DNA-PK and KIT signaling pathways in KIT mutant acute myeloid leukemia

Project description:Acute Myeloid Leukemia (AML) is the most common and aggressive form of acute leukemia, with a 5-year survival rate of just 24%. Over a third of all AML patients harbor activating mutations in kinases, such as the receptor tyrosine kinases FLT3 and KIT. FLT3 and KIT mutations are associated with poor clinical outcomes and lower remission rates in response to standard-of-care chemotherapy. We have recently identified that the core kinase of the non-homologous end joining DNA repair pathway, DNA-PK, is activated downstream of FLT3; and targeting DNA-PK sensitized FLT3-mutant AML cells to standard-of-care therapies. Herein, we investigated DNA-PK as a possible therapeutic vulnerability in KIT mutant AML, using isogenic FDC-P1 myeloid progenitor cell lines transduced with an empty vector or oncogenic mutant KIT (V560G, D816V). Targeted quantitative phosphoproteomic profiling identified phosphorylation of DNA-PK at threonine 2599 in KIT mutant cells, indicative of DNA-PK activation. Accordingly, proliferation assays revealed that KIT mutant FDC-P1 cells were more sensitive to the DNA-PK inhibitors M3814 or NU7441, compared to empty vector controls. DNA-PK inhibition combined with inhibition of KIT signaling via using the kinase inhibitors dasatinib or ibrutinib, or the protein phosphatase 2A activators FTY720 or AAL(S), led to synergistic cell death. Discovery phosphoproteomic analysis of KIT-D816V cells revealed that dasatinib single-agent treatment inhibited ERK1 activity, and M3814 single-agent treatment inhibited Akt/mTOR activity. The combination of dasatinib and M3814 treatment inhibited both ERK/MAPK and Akt/mTOR activity, and induced synergistic inhibition of phosphorylation of transcription regulators including MYC and MYB. This study provides insight into the oncogenic pathways regulated by DNA-PK beyond its canonical role in DNA repair, and demonstrates that DNA-PK is a promising novel therapeutic target for KIT mutant cancers.

2023-01-26 | PXD030214 | panorama

Tracing the development of acute myeloid leukemia in CBL-syndrome

Project description:Comparison of copy number variations of acute myeloid leukemia mononuclear cells and the given cell types collected during complete remission of the acute myeloid leukemia

2014-02-12 | E-MEXP-3997 | biostudies-arrayexpress

E-MTAB-9209

Project description:Transcriptome of primary acute myeloid leukemia (AML) cells treated with AICAr

2025-01-16 | E-MTAB-9209 | ExpressionAtlas

Single-cell RNA sequencing of erythroid and megakaryocytic acute myeloid leukemia patient cells

Project description:Single-cell RNA sequencing was performed on bone marrow mononuclear of a patient with acute myeloid leukemia with erythroid differentiation of the blasts and on peripheral blood mononuclear cells of a patient with acute myeloid leukemia with megakaryocytic differentiation of the blasts. Raw data for this dataset can be found at the EGA under accession EGAS00001006819.

2022-12-05 | E-MTAB-12607 | biostudies-arrayexpress

Spectrum of Mutations in Myeloid Neoplasms

Project description:Patients with myeloid malignancies bearing high-risk cytogenetic abnormalities lack effective therapies and have a poor overall survival. -7/del(7q) is identified in half of high-risk myeloid neoplasms. We recently identified CUX1 to be a haploinsufficient myeloid tumor suppressor gene located within the commonly deleted segment of 7q22. Here we identify the spectrum of somatic mutations that co-occur with loss of CUX1 and chromosome 7 in patients with de novo acute myeloid leukemia (AML) or a therapy-related myeloid neoplasm. -7/del(7q) leukemias have a distinct mutational profile characterized by low frequencies of alterations in major leukemogenic pathways, including genes encoding transcription factors, cohesin, and DNA-methylation-related proteins. In contrast, RAS pathway activating mutations occurred in 40% of -7/del(7q) samples, a significantly higher frequency than other AMLs and higher than previously reported. As targeted therapeutics advance, our data provide guidance for which pathways are most relevant in the treatment of adverse-risk myeloid leukemia.

| phs000759 | dbGaP

E-PROT-137

Project description:Distinct cell type-specific protein signatures in GRN and MAPT genetic subtypes of frontotemporal dementia

2024-06-05 | E-PROT-137 | ExpressionAtlas

E-MTAB-3322

Project description:Targeting epigenetic networks mediated by Prmt1 and Kdm4c in acute myeloid leukemia

2019-05-14 | E-MTAB-3322 | ExpressionAtlas